SCHEMBL3172844

SCHEMBL3172844

O=C(O)N1C[C@@H]2CC[C@@H](O)[C@@H](c3ccc(F)cc3)[C@@H]2C1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 4/20 0.44
PAX8 Q06710 3/20 0.38
NOTUM Q6P988 1/20 0.37
GRIN2B Q13224 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
ATM Q13315 1/20 0.36
MAPT P10636 1/20 0.35
HRH3 Q9Y5N1 1/20 0.34
EPHX2 P34913 1/20 0.34
SIGMAR1 Q99720 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C8 P10632 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
TACR2 P21452 1/20 0.33
TACR3 P29371 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3180166 1.00 TACR1 (0.44) TACR1PAX8NOTUMGRIN2BNPC1
SCHEMBL5989023 1.00 TACR1 (0.44) TACR1PAX8NOTUMGRIN2BNPC1
SCHEMBL3181798 1.00 TACR1 (0.44) TACR1PAX8NOTUMGRIN2BNPC1
SCHEMBL3177278 1.00 TACR1 (0.44) TACR1PAX8NOTUMGRIN2BNPC1
SCHEMBL27648867 1.00 TACR1 (0.44) TACR1PAX8NOTUMGRIN2BNPC1
SCHEMBL3184361 1.00 TACR1 (0.44) TACR1PAX8NOTUMGRIN2BNPC1
SCHEMBL5025626 0.87 RAB9A (0.37) GRIN2BNPC1RAB9AATMEPHX2
SCHEMBL2800431 0.87 RAB9A (0.37) GRIN2BNPC1RAB9AATMEPHX2
SCHEMBL5520664 0.82 HDAC1 (0.48) TACR1
SCHEMBL5522852 0.82 HDAC1 (0.48) TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645790-B2 Hydroisoindoline tachykinin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2010-01-12 US disclosed
US-20080280966-A1 Hydroisoindoline Tachykinin Receptor Antagonists VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) 2008-11-13 US disclosed
US-7345083-B2 Hydroisoindoline tachykinin receptor antagonists MERCK & CO., INC. (US) 2008-03-18 US disclosed
EP-1711465-B1 HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2007-12-26 EP disclosed
US-20070161695-A1 Hydroisoindoline tachykinin receptor antagonists VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) 2007-07-12 US disclosed
US-7217731-B2 Hydroisoindoline tachykinin receptor antagonists MERCK & CO., INC. (US) 2007-05-15 US disclosed
US-20050165083-A1 Hydroisoindoline tachykinin receptor antagonists VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) 2005-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165083-A1 Hydroisoindoline tachykinin receptor antagonists TACR1, TACR2, NPSR1 TACR1 1/4885PAX8 3209/4885NOTUM 4530/4885
US-20070161695-A1 Hydroisoindoline tachykinin receptor antagonists TACR1, TACR2, NPSR1 TACR1 1/4885PAX8 3209/4885NOTUM 4530/4885
US-20080280966-A1 Hydroisoindoline Tachykinin Receptor Antagonists TACR1, TACR2, NPSR1 TACR1 1/4885PAX8 3637/4885NOTUM 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.